Genentech, a unit of Roche, announced on Monday that its immunotherapy blockbuster Tecentriq has won an FDA approval for an aggressive form of lung cancer.
Tecentriq, which already had four treatment approvals — alone or in combination with other therapies — for non-small cell lung cancer, can now be used as a first-line monotherapy for patients whose tumors have a high PD-L1 expression.
Roche is currently running several phase 3 trials of Tecentriq on a range of other cancers including skin, breast, gastrointestinal, gynecological and more.
Sales for Tecentriq, a checkpoint inhibitor in competition with big-name drugs like Keytruda, rose by a staggering 143 percent year-over-year in 2019 as the drug won more approvals for indications related to triple-negative breast cancer and lung cancer.
Read the Reuters report.
